A mesenchymal stem cell culture product and a method for preparing the same are provided. The method for preparing the mesenchymal stem cell culture product includes the following steps. A predetermined quantity of mesenchymal stem cells is seeded in a flat culture device containing a first cell culture medium. When the mesenchymal stem cells proliferate to a target quantity, the first cell culture medium is replaced with a second cell culture medium, and the second cell culture medium is removed after incubation for 18 to 30 hours. A target cell culture medium is added and incubated for 48 to 72 hours. The target cell culture medium is collected repeatedly. The collected target cell culture medium is filtered and concentrated to obtain the mesenchymal stem cell culture product.

A culture container (1) having a guide thread (31) and a plurality of cells (32) that is capable of culturing a regenerative hair follicle germ (30), wherein the culture container (1) is equipped with a first recess (10) and a second recess (20) and the second recess (20) has a second bottom (22) where the guide thread (31) can be positioned in the center of an opening (23) and a method for producing a regenerative hair follicle germ that includes a step for aggregating a cell population including epithelial cells (32a) within the second recess (20) of the culture container (1), a step for aggregating a cell population including mesenchymal cells (32b) within the second recess (20), a step for inserting the guide thread (31) into the second recess (20), and a step for culturing the cell population including epithelial cells (32a) and the mesenchymal cells (32b).

The present disclosure relates to a bioengineering process to derive hair follicles in vitro from the in vitro disposition and differentiation of autologous pluripotent stem cells and dermal papilla stem cells. The present disclosure also relates to the in vitro bioengineering of hypoimmunogenic hair follicles from allogenic pluripotent stem cells and dermal papilla stem cells. The present disclosure also relates to bioengineering of autologous and allogenic hypoimmunogenic hair follicles and hair follicle containing sheets with asymmetric disposition of hair shafts. The present disclosure also relates to a bioengineering process to derive hair follicle containing sheets in vitro from a biodegradable supportive grid and said in vitro derived hair follicles. The present disclosure also relates to the controlled asymmetry of the hair shaft on said hair follicle containing sheets. The present disclosure also relates to the field of cosmetic materials and method for reconstructing hair follicle containing materials in vitro.

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Provided are a protein-coated culture container for classifying, identifying, or specifying mesenchymal stem cells by controlling cell adhesion; and a method of classifying, identifying, or specifying mesenchymal stem cells by using the container.

The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.

The present invention relates to a therapeutic substance and/or medicament and methods relating to the use of said substance and/or medicament for skeletal muscle regeneration using mesenchymal stem cells (MSCs) which can be applied directly or shortly after muscle damage or injury.

Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5− positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.

Disclosed are methods for making individualized mesenchymal stem cell growth factor and exosome compositions and methods of their use to treat skin disorders, hair loss, pain, rheumatoid arthritis, osteoporosis, autism, depression, biopolar disorder, anxiety, celiac disease, and cancer.

The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1.sup.bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.